# EDGAR Filing Document

**Accession Number:** 0000849146
**File Stem:** 0000849146-23-000018
**Filing Date:** 2023-2
**Character Count:** 9571
**Document Hash:** 69b024fce231668b308d428123517018
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000849146-23-000018.hdr.sgml**: 20230203

**ACCESSION NUMBER**: 0000849146-23-000018

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230126

**FILED AS OF DATE**: 20230203

**DATE AS OF CHANGE**: 20230203

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Boyster Julie
- **CENTRAL INDEX KEY:** 0001964003

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35647
- **FILM NUMBER:** 23585752

**MAIL ADDRESS:**
- **STREET 1:** 3300 N. TRIUMPH BLVD, SUITE 700
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lifevantage Corp
- **CENTRAL INDEX KEY:** 0000849146
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 841097796
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 3300 TRIUMPH BLVD
- **STREET 2:** SUITE 700
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043
- **BUSINESS PHONE:** 801-432-9000

**MAIL ADDRESS:**
- **STREET 1:** 3300 TRIUMPH BLVD
- **STREET 2:** SUITE 700
- **CITY:** LEHI
- **STATE:** UT
- **ZIP:** 84043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LIFELINE THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20041019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YAAK RIVER RESOURCES INC
- **DATE OF NAME CHANGE:** 19920703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ANDRAPLEX CORP
- **DATE OF NAME CHANGE:** 19920406

## Ex-24

```
<pre>
POWER OF ATTORNEY
      Know all by these presents that the undersigned hereby constitutes and appoints, Alissa Neufeld and Steven R. Fife, with full power of substitution, as the undersigned's true and lawful attorneys-in-fact to:
      (1)    prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;
      (2)    execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of LifeVantage Corporation (the "Company") and/or 10% holder of the Company's capital stock, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
      (3)    do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
      (4)    take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in such attorneys-in-fact's discretion.
      The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.
      This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of February, 2023.

/s/ Julie Boyster
Julie Boyster

</pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Boyster Julie<br><sub>(Last) (First) (Middle)</sub><br>3300 TRIUMPH BLVD, SUITE 700<br><sub>(Street)</sub><br>LEHI, UT 84043<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Lifevantage Corp [ LFVN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-26 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Marketing Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock<sup>(1)</sup> | 63053 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Performance Restricted Stock Units<sup>(2)</sup> | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 33053.0 | $0.0 | D |  |

---

### Footnotes:

(1) Each stock unit represents a right to receive one share of issuer common stock. 30,000 of these restricted stock units ("RSUs") were acquired pursuant to a restricted stock award granted February 17, 2022, which vests in three equal annual installments on each of February 17, 2023, February 17, 2024, and February 17, 2025, subject to continued service with the Company. 33,053 of these RSUs were acquired pursuant to a restricted stock award granted August 18, 2022, which will vest, subject to the reporting person's continued service with the issuer, as follows: (i) 1/3 of the total number of units will vest on the first anniversary of the grant date and (ii) the remaining units will vest in equal installments as of the first day of each of the eight calendar quarters thereafter.

(2) Each PRSU represents a right to receive one share of issuer common stock, with the total number of units reflecting the number that are eligible to be earned at target-level performance achievement. Upon achievement of the maximum level of the applicable performance criteria, the reporting person may become eligible to earn 200% of the target number of units.

(3) The PRSUs were acquired pursuant to a performance restricted stock award granted August 18, 2022 and will vest only to the extent the specified financial performance criteria are achieved and subject to the reporting person's continued service with the issuer, as follows: (i) 1/3 of the earned award will vest on the first anniversary of the grant date and (ii) the remainder of the earned award will vest in equal installments as of the first day of each of the eight calendar quarters thereafter.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** Alissa Neufeld, Power of Attorney for Julie Boyster  
**Date:** 2023-01-30

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**